Table 1. Comparison of the affinity, potency, and predominating plasma half-life of asialoEPO and rhEPO.

			Percent protection		Plasma half-life, h†
	IC50 for sFc-EPO-R* binding, pM	EC50 for proliferation of UT-7, pM	P-19	PC12	i.v.	i.p.	s.c.
rhEPO	10	20 ± 10	51	31 ± 7	5.6	7.0	5.4
asialoEPO	14	20 ± 10	43	34 ± 4	0.023	0.5	2.5

^*Soluble Fc-EPO-R fusion construct.

^†Plasma half-lives are terminal phase except for i.v. asialoEPO, which is initial phase.